If you are interested in joining an organization that is focused on hard work, excellence, and scientific advancement, please reach out to us using the form below.
Stuart Therapeutics controls the exclusive worldwide rights to the PolyCol technology and associated patents through license. We are committed to the development of important new innovations in therapeutics for chronic ophthalmic indications and are interested in strategic partner relationships that will extend and accelerate our impact.
Stuart Therapeutics has recently completed its Phase 2 clinical trial for its first drug candidate, ST-100 for Dry Eye Disease. The company has also completed extensive in vitro and in vivo research to profile the multiple amino acid sequence variants of the PolyCol platform, including their impact on accelerating tissue healing and reduction of inflammation in other important ophthalmic indications.